Accueil>>Signaling Pathways>> Antibody-drug Conjugate/ADC Related>> ADC Linker>>Amino-PEG2-C2-acid

Amino-PEG2-C2-acid

Catalog No.GC63660

L'amino-PEG2-C2-acide est un lieur clivable PEG ADC À 3 unités utilisé dans la synthèse de conjugués anticorps-médicament (ADC). L'amino-PEG2-C2-acide est également un lieur PROTAC À base de PEG qui peut être utilisé dans la synthèse des PROTAC.

Products are for research use only. Not for human use. We do not sell to patients.

Amino-PEG2-C2-acid Chemical Structure

Cas No.: 791028-27-8

Taille Prix Stock Qté
25 mg
45,00 $US
En stock
50 mg
72,00 $US
En stock
100 mg
108,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

Amino-PEG2-C2-acid is a cleavable 3 unit PEG ADC linker used in the synthesis of antibody-drug conjugates (ADCs). Amino-PEG2-C2-acid is also a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins.

[1]. Antibody drug conjugate, intermediate, preparation method, pharmaceutical composition and uses thereof. WO2016197946A1.

Avis

Review for Amino-PEG2-C2-acid

Average Rating: 5 ★★★★★ (Based on Reviews and 15 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Amino-PEG2-C2-acid

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.